110 related articles for article (PubMed ID: 16600800)
1. Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models.
Xie X; Eberding A; Madera C; Fazli L; Jia W; Goldenberg L; Gleave M; Guns ES
J Urol; 2006 May; 175(5):1926-31. PubMed ID: 16600800
[TBL] [Abstract][Full Text] [Related]
2. Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.
Zheng X; Chang RL; Cui XX; Avila GE; Hebbar V; Garzotto M; Shih WJ; Lin Y; Lu SE; Rabson AB; Kong AN; Conney AH
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3444-51. PubMed ID: 16740769
[TBL] [Abstract][Full Text] [Related]
3. Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model.
Miyake H; Hara S; Arakawa S; Kamidono S; Hara I
Br J Cancer; 2001 Mar; 84(6):859-63. PubMed ID: 11259104
[TBL] [Abstract][Full Text] [Related]
4. Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer.
Musende AG; Eberding A; Jia W; Ramsay E; Bally MB; Guns ET
Prostate; 2010 Sep; 70(13):1437-47. PubMed ID: 20687217
[TBL] [Abstract][Full Text] [Related]
5. Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy.
Jia WW; Bu X; Philips D; Yan H; Liu G; Chen X; Bush JA; Li G
Can J Physiol Pharmacol; 2004 Jul; 82(7):431-7. PubMed ID: 15389289
[TBL] [Abstract][Full Text] [Related]
6. Different effect of paclitaxel on primary tumor mass, tumor cell contents, and metastases for four experimental human prostate tumors expressing luciferase.
El Hilali N; Rubio N; Blanco J
Clin Cancer Res; 2005 Feb; 11(3):1253-8. PubMed ID: 15709196
[TBL] [Abstract][Full Text] [Related]
7. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells.
Vadgama JV; Wu Y; Shen D; Hsia S; Block J
Anticancer Res; 2000; 20(3A):1391-414. PubMed ID: 10928049
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER microspheres) and radiation.
Lapidus RG; Dang W; Rosen DM; Gady AM; Zabelinka Y; O'Meally R; DeWeese TL; Denmeade SR
Prostate; 2004 Feb; 58(3):291-8. PubMed ID: 14743469
[TBL] [Abstract][Full Text] [Related]
9. Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model.
Ahmed S; Johnson CS; Rueger RM; Trump DL
J Urol; 2002 Aug; 168(2):756-61. PubMed ID: 12131364
[TBL] [Abstract][Full Text] [Related]
10. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells.
Chen Z; Koeneman KS; Corey DR
Cancer Res; 2003 Sep; 63(18):5917-25. PubMed ID: 14522918
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway.
Zhang AL; Russell PJ; Knittel T; Milross C
Prostate; 2007 Nov; 67(15):1630-40. PubMed ID: 17823933
[TBL] [Abstract][Full Text] [Related]
12. 1α,25-Dihydroxyvitamin D
Ben-Eltriki M; Deb S; Guns EST
J Steroid Biochem Mol Biol; 2021 May; 209():105828. PubMed ID: 33493594
[TBL] [Abstract][Full Text] [Related]
13. Liposomal imatinib-mitoxantrone combination: formulation development and therapeutic evaluation in an animal model of prostate cancer.
Pinto AC; Moreira JN; Simões S
Prostate; 2011 Jan; 71(1):81-90. PubMed ID: 20607721
[TBL] [Abstract][Full Text] [Related]
14. Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy.
Musende AG; Eberding A; Wood C; Adomat H; Fazli L; Hurtado-Coll A; Jia W; Bally MB; Guns ET
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1085-95. PubMed ID: 19301006
[TBL] [Abstract][Full Text] [Related]
15. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
16. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
17. pH modulation using CsCl enhances therapeutic effects of vitamin D in LNCaP tumor bearing mice.
Guns ES; Xie X; Fedoruk M; Madera C; Cowell S; Mayer LD; Skov K; Gleave ME; Kozlowski P
Prostate; 2005 Aug; 64(3):316-22. PubMed ID: 15754319
[TBL] [Abstract][Full Text] [Related]
18. Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer.
Corcoran NM; Costello AJ
BJU Int; 2005 Sep; 96(4):640-6. PubMed ID: 16104925
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer model.
Guinan P; Shaw M; Mirochnik Y; Slobodskoy L; Ray V; Rubenstein M
Methods Find Exp Clin Pharmacol; 1998 Nov; 20(9):739-42. PubMed ID: 10022026
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of microtubule-active drugs followed by ketoconazole in human metastatic prostate cancer cell lines.
Blagosklonny MV; Dixon SC; Figg WD
J Urol; 2000 Mar; 163(3):1022-6. PubMed ID: 10688042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
